There are different podocentric therapeutic options for DN and other glomerulopathies, such as angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB), glucocorticoids, CNIs, and even Rituximab [32]. This evidence concerns the gene ACE and glomerular disorder.